Analyses of large registries observed a reduced incidence of MACE in patients with RA or other inflammatory arthritis treated with anti-TNF-α biologic drugs, compared to patients treated with the traditional disease-modifying drugs. Here, TNF is linked to rheumatoid arthritis.